TrialDiabetes, obesity & metabolism2022

The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.

Jack A Sargeant et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.